Trial: 202107015

TK IMPACT: Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) with or without the Addition of DiviTum(R) Serum Thymidine Kinase 1 (TK1) Activity Testing: Physician Decision Impact Study

Phase

N/A

Principal Investigator

Bagegni, Nusayba

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov